Dr. Min Liu obtained her Ph.D. from University of Fudan in 2007. And now, she works as an associated professor at School of Pharmacy, Fudan University. Her major research focused on improving the antitumor effect of chemotherapy drugs using D-peptides. She designed three D-peptides, and found these D-peptides not only had better salability in vivo, but also enhanced the binding activity with receptor. Binding with receptor, D-peptides could produce a series of biological effects and increase the delivery of chemotherapy drug into tumor tissue.
Active peptide; Non-viral gene vector; Lymphatic drug delivery system
Education
Ph.D. Pharmaceutics, Fudan University, China, 2003~2007
M.S. Biochemistry, Pharmacy school of Huaxi, Sichuan University, China, 1993~1996
B.S. Pharmacy, Pharmacy school of Huaxi, Sichuan University, China, 1986~1991
Professional Experiences
2007.1-present
Associate Professor in the Department of Pharmaceutics, school of Pharmacy, Fudan University, Shanghai, China
2000.1-2006.12
Lecturer in the Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, China
1996.7-1999.12
Assistant in the Department of Targeting Pharmaceuticals, Institute of Pharmacy, School of Pharmacy, Shanghai Medical University, Shanghai, China
Teaching Activities
2002.02-Present
“Physical Pharmacy” for both undergraduate and graduate students; and “Drug Targeting Delivery Systems” and “Pharmaceuticals” for undergraduates
Tutor of 10 master students; Help instructing 5 master students and 2 Ph.D. students
Grants & Projects
1. pH controlled polymeric micelles for therapy of lymphatic metastatic tumor. (NSFC, 30772655, 2003-2007)
2. Study on co-administration of Retro-inverso Bradykinin and polymeric micelles for
therapy of brain glioma. (NSFC, 81473148, 2014-2018)
Awards & Honors
1. Silver Prize of “Shanghai Excellent Patent Award” by Shanghai Intellectual Property Office (2016, No. 2016Z168)
2. Second prize of “Shanghai pharmaceutical science and technology award” by Shanghai Pharmaceutical Association (2009)
Selected Publications（latest 5 yrs，<20 papers）
1. Bingxia Su#, Ruifeng Wang#, Zuoxu Xie, Huitong Ruan, Jichen Li, Cao Xie, Weiyue Lu, Jing Wang, Dongli Wang, Min Liu* Effect of Retro-inverso Isomer of Bradykinin on Size-dependent Penetration of Blood-brain Tumor Barrier. Small (SCI, IF=8.643). 2017, 14(7). DOI:10.1002/smll.201702331
2. Zuoxu Xie#, Qing Shen, Cao Xie,Weiyue Lu, Chunmei Peng, XiaoliWei, Xue Li, Bingxia Su, Chunli Gao, Min Liu* Retro-inverso bradykinin opens the door of blood–brain tumor barrier for nanocarriers in glioma treatment. Cancer Letters (SCI, IF=6.375). 2015, 369(1):144–151.
3. Xue Li#, Zuoxu Xie, Cao Xie, Weiyue Lu, Chunli Gao, Henglei Ren, Man Ying, Xiaoli Wei, Jie Gao, Bingxia Su, Yachao Ren, and Min Liu* D?SP5 Peptide-Modified Highly Branched Polyethylenimine for Gene Therapy of Gastric Adenocarcinoma. Bioconjugate Chemistry (SCI, IF=4.818), 2015, 26(8), 1494?1503.
4. Jing Wang#, Yang Lei, Cao Xie, Weiyue Lu, Ernst Wagner, Zuoxu Xie, Jie Gao , Xiaoyu Zhang , Zhiqiang Yan , and Min Liu* Retro-Inverso C-endR Peptide-Mediated Polyethyleneimine for Intracranial Glioblastoma-targeting Gene Therapy. Bioconjugate Chemistry (SCI, IF=4.818), 2014, 25(2), 414-423.
5. Ying Li#, Yang Lei, Ernst Wagner, Cao Xie, Weiyue Lu, Jianhua Zhu, Jie Shen, Jing Wang, and Min Liu* Potent Retro-Inverso D?Peptide for Simultaneous Targeting of Angiogenic Blood Vasculature and Tumor Cells. Bioconjugate Chemistry (SCI, IF=4.818). 2013, 24(1):133-43.
6. Min Liu#, Xue Li, Zuoxu Xie, Cao Xie, Changyou Zhan, Xuefeng Hu, Qing Shen, Xiaoli Wei, Bingxia Su, Jing Wang, Weiyue Lu* D-Peptides as Recognition Moleculesand Therapeutic Agents. The chemical record (SCI, IF=3.858). 2016, 16(4), 1772–1786.
7. Xue Li#, Qing Dong , Zhiqiang Yan, Weiyue Lu, Lingling Feng, Cao Xie, Zuoxu Xie, Bingxia Su, Min Liu* MPEG-DSPE polymeric micelle for translymphatic chemotherapy of lymph node metastasis. International Journal of Pharmaceutics (SCI, IF=3.649). 2015, 487(1-2): 8–16.
8. Jing Wang#, Yang Lei, Cao Xie, Weiyue Lu, Zhiqiang Yan, Jie Gao, Zuoxu Xie, Xiaoyu Zhang, Min Liu? Targeted gene delivery to glioblastoma using a C-end rule RGERPPR peptide- functionalised polyethylenimine complex. International Journal of Pharmaceutics (SCI, IF=3.649). 2013, 458(1): 48–56.
9. Yang Lei#, Jing Wang, Cao Xie, Ernst Wagner, Weiyue Lu, Ying Li, Xiaoli Wei, Jibin Dong, Min Liu* Glutathione-sensitive RGD-poly(ethylene glycol)-SS-polyethylenimine for intracranial glioblastoma targeted gene delivery. The Journal of Gene Medicine (SCI, IF=2.524). 2013, 15(8-9): 291–305.
Patents
1. Patent No. US 7,005,426 B2; RU 2280750 C2; CN ZL 00 1 15752.3
Folic acid-polysaccharide complex, its preparation method and pharmaceutical composition containing the same as active component
Weiyue Lu, Min Liu, Jun Pan
2. Patent No. ZL 201110286883.3
A dual-targeted D configuration peptide and its delivery system.
Min Liu, Ying Li, Weiyue Lu, Cao Xie, Qing Dong, Yang Lei, Jing Wang
3. Patent No. ZL 201310111290.2
D configuration peptide and its gene delivery system based on tumor targeting and Tumor tissue penetration
Min Liu, Jing Wang, Weiyue Lu, Cao Xie, Yang Lei, Zuoxu Xie
4. Application Patent No. 201410199567.6
Peptides binding with bradykinin receptor and its application.
Min Liu, Zuoxu Xie, Weiyue Lu, Cao Xie, Xue Li
5. Application Patent No. 2017108730129
An imidazole derivative and its gene delivery system.
Min Liu, Jing Wang, Xuefeng Hu, Dongli Wang, Jie Song, Cao Xie
